Tract Bio is a biotechnology company discovering and developing novel therapies to transform the treatment of cancer and inflammatory disease. The Company’s breakthrough stem cell discovery platform, stemECHO™, allows for reliable, high-volume generation of pure stem cell libraries in their ground-state while preserving the functional, genetic and epigenetic integrity of the original stem cell. The stemECHO™ platform has identified disease-associated stem cells in cancer and inflammatory diseases, including potential treatments for esophageal adenocarcinoma, lung, ovarian, pancreatic and gastric cancer, as well as COPD, Idiopathic Pulmonary Fibrosis, Cystic Fibrosis and Crohn’s Disease. Tract is advancing TP-101, a novel drug combination identified using stemECHO™ that targets a common mechanism among disease-associated stem cells in cancer. The Company is also developing novel therapies for inflammatory diseases.
Company Details
- Employees
- 5
- Address
- 29 S Main St, Boston,massachusetts 06107,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://tractbio.com
- HQ
- Boston, Massachusetts
Tract Bio Questions
Tract Bio's website is http://tractbio.com
Tract Bio's LinkedIn profile is https://www.linkedin.com/company/tract-bio
Tract Bio has
5 employees.
View email and phone details for 5
employees at Tract Bio.
Tract Bio's industry is
Biotechnology Research
Tract Bio's top competitors are
Eli Lilly And Company,
Bvm Consulting, Llc,
Elevar Therapeutics,
Ergot Biosciences,
Argot Partners,
Uh Partners,
Minerva Neurosciences,
Stemcellerant,
Bvm Consulting Inc.,
Delta Point Group.
Tract Bio's categories are Biotechnology Research
